289 related articles for article (PubMed ID: 16690960)
21. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Wang Y; Zhang XH; Wang HL
Can J Physiol Pharmacol; 2011 May; 89(5):345-54. PubMed ID: 21619414
[TBL] [Abstract][Full Text] [Related]
22. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of profilin, cofilin-2 and LIMK2 in cultured pulmonary artery smooth muscle cells and in pulmonary arteries of monocrotaline-treated rats.
Dai YP; Bongalon S; Tian H; Parks SD; Mutafova-Yambolieva VN; Yamboliev IA
Vascul Pharmacol; 2006 May; 44(5):275-82. PubMed ID: 16524786
[TBL] [Abstract][Full Text] [Related]
24. Characterization of erectile function in monocrotaline-treated pulmonary hypertensive rats.
Gur S; Kadowitz PJ; Thammasitboon S; Lasky JA; Hellstrom WJ
J Androl; 2009; 30(5):495-504. PubMed ID: 19201699
[TBL] [Abstract][Full Text] [Related]
25. [TRPC6 mediates the enhancements of pulmonary arterial tone and intracellular Ca2+ concentration of pulmonary arterial smooth muscle cells in pulmonary hypertension rats].
Zhang MF; Liu XR; Yang N; Lin MJ
Sheng Li Xue Bao; 2010 Feb; 62(1):55-62. PubMed ID: 20179889
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin converting enzyme activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension.
Kay JM; Keane PM; Suyama KL; Gauthier D
Thorax; 1982 Feb; 37(2):88-96. PubMed ID: 6281933
[TBL] [Abstract][Full Text] [Related]
27. Effect of Angiotensin II Type 1 receptor blocker on cardiac angiotensin-converting enzyme and chymase-like activities, and cardiac fibrosis in cardiomyopathic hamsters.
Shimizu M; Tanaka R; Uchida M; Orito K; Shimamura S; Yamane Y
J Vet Med Sci; 2006 Mar; 68(3):227-33. PubMed ID: 16598165
[TBL] [Abstract][Full Text] [Related]
28. [Role of angiotensin II-forming enzymes, angiotensin-converting enzyme and chymase].
Takai S; Miyazaki M
Nihon Rinsho; 1999 May; 57(5):1078-83. PubMed ID: 10361438
[TBL] [Abstract][Full Text] [Related]
29. A novel ACE2 activator reduces monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT and TGF-β cascades with restored caveolin-1 expression.
Haga S; Tsuchiya H; Hirai T; Hamano T; Mimori A; Ishizaka Y
Exp Lung Res; 2015 Feb; 41(1):21-31. PubMed ID: 25275723
[TBL] [Abstract][Full Text] [Related]
30. CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats.
Cui B; Cheng YS; Dai DZ; Li N; Zhang TT; Dai Y
Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):169-75. PubMed ID: 18986320
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension.
van Suylen RJ; Smits JF; Daemen MJ
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1423-8. PubMed ID: 9603118
[TBL] [Abstract][Full Text] [Related]
32. Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis.
Bruce E; Shenoy V; Rathinasabapathy A; Espejo A; Horowitz A; Oswalt A; Francis J; Nair A; Unger T; Raizada MK; Steckelings UM; Sumners C; Katovich MJ
Br J Pharmacol; 2015 May; 172(9):2219-31. PubMed ID: 25522140
[TBL] [Abstract][Full Text] [Related]
33. Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor.
Han DD; Wang Y; Zhang XH; Liu JR; Wang HL
Can J Physiol Pharmacol; 2012 Apr; 90(4):445-54. PubMed ID: 22448962
[TBL] [Abstract][Full Text] [Related]
34. The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling.
Zeng Z; Li Y; Jiang Z; Wang C; Li B; Jiang W
Cardiovasc Ther; 2010; 28(1):23-9. PubMed ID: 20074256
[TBL] [Abstract][Full Text] [Related]
35. The effects of gender difference on monocrotaline-induced pulmonary hypertension in rats.
Bal E; Ilgin S; Atli O; Ergun B; Sirmagul B
Hum Exp Toxicol; 2013 Jul; 32(7):766-74. PubMed ID: 23821593
[TBL] [Abstract][Full Text] [Related]
36. Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.
Lu J; Shimpo H; Shimamoto A; Chong AJ; Hampton CR; Spring DJ; Yada M; Takao M; Onoda K; Yada I; Pohlman TH; Verrier ED
J Thorac Cardiovasc Surg; 2004 Dec; 128(6):850-9. PubMed ID: 15573069
[TBL] [Abstract][Full Text] [Related]
37. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Schermuly RT; Kreisselmeier KP; Ghofrani HA; Samidurai A; Pullamsetti S; Weissmann N; Schudt C; Ermert L; Seeger W; Grimminger F
Circ Res; 2004 Apr; 94(8):1101-8. PubMed ID: 15031263
[TBL] [Abstract][Full Text] [Related]
38. Roles of vascular angiotensin converting enzyme and chymase in two-kidney, one clip hypertensive hamsters.
Jin D; Takai S; Shiota N; Miyazaki M
J Hypertens; 1998 May; 16(5):657-64. PubMed ID: 9797177
[TBL] [Abstract][Full Text] [Related]
39. Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease.
Todorovich-Hunter L; Dodo H; Ye C; McCready L; Keeley FW; Rabinovitch M
Am Rev Respir Dis; 1992 Jul; 146(1):213-23. PubMed ID: 1626806
[TBL] [Abstract][Full Text] [Related]
40. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension.
Miyauchi T; Yorikane R; Sakai S; Sakurai T; Okada M; Nishikibe M; Yano M; Yamaguchi I; Sugishita Y; Goto K
Circ Res; 1993 Nov; 73(5):887-97. PubMed ID: 8403258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
